Contact Us Donate Site Guide
NARAL Pro-Choice Missouri
NARAL Pro-Choice Missouri

Take Action

Tell Gov. Nixon to Raise the Standard of Care for Rape Victims!

Tell the Obama Administration Its Decision on Plan B® Is Unacceptable

End the Discrimination of Raped Servicewomen

» more action alerts

Choice Headlines

NARAL Pro-Choice Missouri opposes second parent notification for minors

NARAL Pro-Choice Missouri voices opposition to increased restrictions on abortion

NARAL Pro-Choice Missouri Speaks Out Against 72-hour Abortion Waiting Period

» more choice headlines

Press Releases


» more press releases


In September of 2000, after more than a decade of delays caused by anti-choice activists and lawmakers, mifepristone (RU 486), received final approval from the Food and Drug Administration (FDA).

Mifepristone has been available to women in Europe for over a decade. It has been shown to be a safe and effective alternative to surgical abortion following extensive clinical trials in France, Great Britain, and Sweden. But prior to 2000, this important reproductive health option had been unavailable to women in the U.S., largely due to anti-choice politics.

Mifepristone offers women an early, safe, and effective medical alternative to surgical abortion. Under the current FDA-approved regimen it is administered by a woman's doctor and requires several visits to a clinic or doctor's office. The drug also holds promise for the treatment of other health conditions such as breast cancer, endometriosis, and Cushing's disease.

Anti-choice lawmakers are now moving to block access to this drug. At the federal and state levels, lawmakers have proposed legislation designed to curtail the availability of mifepristone and limit the number of doctors who can prescribe it. Such legislation would effectively destroy the promise of this important medical advancement.
Analysis of S.B. 330 (2013)
Ostensibly a bill regulating “baked goods”, on page 13, it forbids Iowa-style medication abortions (Telemed).  In Iowa, physicians can remotely ...
Analysis of H.C.S. S.C.S. S.B. 126 (2013)
This bill includes provisions which we believe could further restrict access to women’s reproductive health care.
Talking points for HB1274 (2012) (Abortion-Inducing Drugs Safety Act)
H.B. 1274 (Abortion-Inducing Drugs Safety Act) (Koenig) From Pamela L. Sumners, Esq., Executive Director Medical Facts/Burden on Access to Abortion Care—Suggestions for ...

Home | Take Action | Issues | In Our State | News | About Us | Support Us
Pregnant? Need Help? | Contact Us | Get E-mail Alerts | Privacy Policy

©NARAL Pro-Choice Missouri

©NARAL Pro-Choice Missouri